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Abstract: The Ebola virus (EBOV) envelope glycoprotein (GP) mediates the fusion of the virion
membrane with the membrane of susceptible target cells during infection. While proteolytic cleavage
of GP by endosomal cathepsins and binding of the cellular receptor Niemann-Pick C1 protein (NPC1)
are essential steps for virus entry, the detailed mechanisms by which these events promote membrane
fusion remain unknown. Here, we applied single-molecule Förster resonance energy transfer
(smFRET) imaging to investigate the structural dynamics of the EBOV GP trimeric ectodomain, and
the functional transmembrane protein on the surface of pseudovirions. We show that in both contexts,
pre-fusion GP is dynamic and samples multiple conformations. Removal of the glycan cap and NPC1
binding shift the conformational equilibrium, suggesting stabilization of conformations relevant to
viral fusion. Furthermore, several neutralizing antibodies enrich alternative conformational states.
This suggests that these antibodies neutralize EBOV by restricting access to GP conformations relevant
to fusion. This work demonstrates previously unobserved dynamics of pre-fusion EBOV GP and
presents a platform with heightened sensitivity to conformational changes for the study of GP function
and antibody-mediated neutralization.
Keywords: Ebola virus; envelope glycoprotein; conformational dynamics; single-molecule FRET;
virus entry
1. Introduction
Ebola virus (EBOV) disease outbreaks in West and Sub-Saharan Africa have occurred since the
emergence of the virus in 1976 [1]. The 2014–2016 West African outbreak resulted in more than 28,000
cases and 11,000 fatalities, and the current outbreak in the Democratic Republic of Congo continues to
claim lives. The most promising vaccine and therapeutic target for EBOV infection is the envelope
glycoprotein (GP), which coordinates viral-host membrane fusion. GP exists as a trimer of GP1–GP2
heterodimers which resides on the surface of the EBOV virion [2]. GP1 mediates virus attachment and
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receptor binding, and GP2 promotes membrane fusion. Following attachment to the cell surface, EBOV
is trafficked to late endosomes where GP1 is proteolytically cleaved by host cathepsins to remove the
mucin-like domain (muc) and the glycan cap, forming GPCL [3,4]. This cleavage event exposes the
binding site for the host receptor for EBOV, Niemann-Pick C1 protein (NPC1). Binding of GPCL to the
luminal domain C of NPC1 (NPC1-C) is necessary, but not sufficient, to trigger GP-mediated fusion of
the viral and endosomal membranes [5–9]. As the sole surface antigen of EBOV, GP is also the target of
host neutralizing antibodies (nAbs), which may function to inhibit conformational changes required
for membrane fusion [10].
Atomic resolution structures of the pre-fusion muc-deleted, transmembrane (TM)-deleted GP
ectodomain (GP∆TM) in unliganded and antibody-bound states depict a conformation in which the
fusion loop of GP2 is sequestered in a hydrophobic cleft, which spans the interface of two neighboring
protomers [2,11–13]. Structures of uncleaved GP and GPCL in complex with NPC1-C depict similar
global conformations of the GP2 fusion loop with respect to GP1 [14,15]. In contrast, structures of
post-fusion GP2 fragments indicate a loop-to-helix transition in the heptad repeat 1 (HR1) region of
GP2, which would translate the fusion loop away from the surface of the virion and toward the target
membrane, similar to that described for influenza hemagglutinin [16]. In the post-fusion conformation
of GP, HR1 ultimately forms a single helix antiparallel to HR2 [17,18]. Thus, structural models indicate
the endpoint conformations that GP adopts during membrane fusion, implying that GP is capable of
undergoing large-scale conformational changes. However, direct evidence for the trajectory connecting
the pre- and post-fusion conformations, including the significance of GP cleavage and NPC-1 binding
in promoting this conformational rearrangement, is currently lacking.
Here, we sought to visualize the conformational dynamics of GP during the steps preceding
membrane fusion. We first designed a single-molecule Förster resonance energy transfer (smFRET)
imaging approach to detect real-time changes in the conformation of the trimeric GP ectodomain
(GP∆TM), as well as functional, pseudovirus-associated GP (GP∆muc) with an intact transmembrane
domain. We found that both GP∆TM and GP∆muc are intrinsically dynamic. GP∆TM exhibits a
predominant conformational state that is consistent with existing structures determined by x-ray [2,11].
This conformation is also sampled by pseudovirion-associated GP∆muc. Removal of the glycan cap
of GP∆muc and NPC1 binding destabilize the conformation depicted by crystallography, suggestive
of promotion of conformations on pathway to fusion. Thus, glycan cap removal may play an active
role in promoting EBOV entry beyond exposing the receptor-binding site. Finally, we also find that
neutralizing antibodies bound to GP∆muc enrich for alternative conformations, thus destabilizing
access to this entry-relevant conformation, which may thereby block virus entry.
2. Materials and Methods
2.1. Cell Lines
HEK293T cells (American Type Culture Collection, Manassas, VA, USA; ATCC) were maintained
at 37 ◦C and 5% CO2 in DMEM complete, consisting of Dulbecco’s Modified Eagle medium
(DMEM; ThermoFisher, Waltham, MA, USA) with 10% BenchMark Fetal Bovine Serum (Gemini
Bio-Products, West Sacramento, CA, USA), 1% L-Glutamine (Thermo Fisher, Waltham, MA, USA), and
1% penicillin-streptomycin (Thermo Fisher, Waltham, MA, USA). FreeStyle 293-F cells (Thermo Fisher,
Waltham, MA, USA) were cultured in FreeStyle 293 Expression Medium (Thermo Fisher, Waltham,
MA, USA) at 37 ◦C and 8% CO2.
2.2. Plasmids
The EBOV GP∆muc Mayinga variant (Genbank accession number NP_066246) was used in all
pseudoparticle experiments. GP∆muc lacks residues 309–489 corresponding to the mucin-like domain.
EBOV GP∆TM is a derivative of the GP∆muc Mayinga variant with deletions of residues 313–463 of
the mucin domain and residues 633–676 of the transmembrane domain, and encodes a C-terminal
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foldon trimerization peptide and 6X His tag. For single-molecule FRET experiments, GP∆TM and
GP∆muc were modified such that the nucleotide sequence encoding A1 and A4 peptides were inserted
at the N-terminal positions of GP1 and GP2, respectively. A1 was inserted between amino acid 32 and
33 of GP1 (Figure 1b). A4 was inserted between amino acid 501 and 502 of GP2 (Figure 1b). pNL4.3R-E-
(NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. Nathaniel Landau) was used
to generate retroviral pseudoparticles, as described below. Plasmids encoding luminal domain C of
NPC1 [6], and KZ52 [19] have been previously described.
2.3. Protein Production and Purification
Soluble NPC1-C containing an N-terminal FLAG and 6X His tag were produced by transfection
in FreeStyle 293-F cells (Thermo Fisher, Waltham, MA, USA) with polyethyleneimine (PEI MAX,
Polysciences, Warrington, PA, USA). Six days post-transfection, cell culture supernatant containing
soluble protein was harvested and purified using PerfectPro Ni-NTA Agarose beads (PRIME
GmbH, Neuss, Germany). Purified NPC1-C was dialyzed 20 mM Tris-HCl, 100 mM NaCl, 2 mM
2-mercaptoethanol, and 10% glycerol and concentrated in Vivaspin 6 ultracentrifugation spin columns
(Sartorius, Gottingen, Germany). NPC1-C was stored at −80 ◦C prior to use. KZ52 was produced by
transfection of plasmids encoding heavy and light chains into FreeStyle 293-F cells with PEI. At 3 days
post-transfection, the cell culture supernatant was collected and replaced with fresh medium. The
supernatant was collected again at 6 days post-transfection. The 3- and 6-day supernatant fractions
were pooled, and KZ52 antibody was extracted using standard protein A affinity chromatography.
After eluting from protein A in 0.2 M citric acid pH3, KZ52 was dialyzed into PBS and stored at −80 ◦C
prior to use. GP∆TM was produced as described below.
2.4. Infectivity and Neutralization Assays
Retroviral pseudoparticles were generated with all tagged GP∆muc 32-A1/501-A4 or all wild-type
GP∆muc by transfection of HEK293T cells with Lipofectamine 3000 Reagent (Thermo Fisher, Waltham,
MA, USA) at 1:5 GP-encoding plasmid:pNL4-3.R-E- backbone. Virus was harvested 48 h after
transfection, concentrated 10- or 20-fold with Lenti-X Concentrator (Clontech, Mountain View, CA,
USA) and resuspended in DMEM complete. The infectivity or neutralization of retroviral pseudovirions
was determined by Firefly Luciferase reporter gene activity using the Luciferase Assay System (Promega,
Madison, WI, USA). HEK293T cells were seeded 24 h before infection in an opaque 96-well clear bottom
white microplate (Thermo Fisher, Waltham, MA, USA). For infectivity assays, cells were infected
directly with pseudovirions. For neutralization assays, virus was incubated with 15 µg/mL of antibody
(unless otherwise stated) at 37 ◦C for 30 min before addition of the virus-antibody mixture to cells.
Cell culture media was replaced 24 h after infection. 48 h post-infection, cells were washed with PBS
(Thermo Fisher, Waltham, MA, USA), lysed with Cell Culture Lysis Reagent (Promega, Madison, WI,
USA) and firefly luciferase reporter gene activity was detected using a Synergy H1 microplate reader
(BioTek Instruments, Winooski, VT, USA). Infectivity of rVSV-GP∆muc was assayed as previously
described [3].
2.5. sNPC1-C ELISA
Pseudovirions were produced as described above by co-transfection of plasmids encoding HIV-1
backbone and either GP∆muc or GP∆muc 32-A1/501-A4, at a 1:1 ratio. Immediately before use,
pseudoparticles were concentrated and treated for 1 h at 37 ◦C with 0.25 mg/mL thermolysin (Promega,
Madison, WI, USA) in 50 mM Tris-HCl pH8, 0.5 mM CaCl2. The uncleaved control was incubated in the
same way in the absence of thermolysin. Reactions were terminated with EDTA. ELISAs to determine
NPC1-C binding to GP∆muc or GPCL were preformed based on previously published methods [6,20].
Briefly, high-binding 96-well ELISA plates (Thermo Fisher, Waltham, MA, USA) were coated with
concentrated pseudoparticles diluted in PBS. Plates were blocked with 2% milk containing 3% bovine
serum albumin in PBS. Unbound virus was washed off and 10-fold dilutions of NPC1-C (0–40 µg/mL)
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were added. Bound NPC1-C was detected with the horseradish peroxidase-conjugated anti-FLAG
antibody (Millipore Sigma, Burlington, MA, USA) followed by Ultra-TMB substrate (Thermo Fisher,
Waltham, MA, USA). All incubations were performed for 1 h at 37 ◦C.
2.6. Immunoblots
Denatured samples containing pseudovirions were run on 10% polyacrylamide gels (Millipore
Sigma, Burlington, MA, USA) and transferred to nitrocellulose membranes. Membranes were blocked
overnight at 4 ◦C. The mAb H3C8 [21] was used to detect GP and GPCL, and the mAb B1217M (GeneTex,
Irvine, Ca, USA) to detect the HIV-1 structural protein p24. All primary antibodies were detected with
a horseradish peroxidase-conjugated rabbit anti-mouse IgG Fc (Thermo Fisher, Waltham, MA, USA).
2.7. GP∆TM Production and Labeling for smFRET Imaging
GP∆TM was produced by transfection in FreeStyle 293-F cells (Thermo Fisher, Waltham, MA,
USA) with polyethyleneimine (PEI MAX, Polysciences, Warrington, PA, USA). Wild-type GP∆TM
and GP∆TM 32-A1/501-A4 expression constructs were co-transfected at a ratio of 2:1. At 6 days
post-transfection, cell culture supernatant containing soluble protein was harvested and purified
using PerfectPro Ni-NTA Agarose beads (PRIME GmbH, Neuss, Germany). Purified GP∆TM was
exchanged into PBS supplemented with 10mM MgOAc using Vivaspin 6 ultracentrifugation spin
columns (Sartorius, Gottingen, Germany) and then incubated overnight at room temperature with 5
µM each of fluorophores LD550 and LD650 (Lumidyne Technologies, New York, NY, USA) conjugated
to coenzyme A (CoA; Millipore Sigma, Burlington, MA, USA) and 5µM of the labeling enzyme Acyl
carrier protein synthase (AcpS). Labeled protein was purified away from free dye and enzyme via size
exclusion chromatography, on a Superdex 200 Increase 10/300 GL column (GE Healthcare, Chicago, IL,
USA) in PBS. Fractions containing GP∆TM were pooled and concentrated to 1–2 mg/mL. Aliquots
were flash-frozen in liquid nitrogen and stored at −80 ◦C until use.
2.8. Pseudovirus Production and Labeling for smFRET Imaging
Retroviral pseudoparticles containing a single fluorescently labeled GP protomer per virion were
generated by transfection of HEK293T cells with Lipofectamine 3000 Reagent (Thermo Fisher, Waltham,
MA, USA) at a 5:1 ratio of pNL.4-3R-E- over plasmid encoding GP. Plasmid encoding GP consisted of a
50:1 mixture of plasmid encoding wild-type GP∆muc:GP∆muc 32-A1/501-A4. Virus was harvested 48
h after transfection, concentrated and labeled with fluorophores as described [22]. Briefly, harvested
virus was concentrated by ultracentrifugation through a 10% sucrose cushion for 2 h at 25,000× g,
resuspended in labeling buffer (50 mM HEPES pH 7.5, 10 mM MgOAc) and incubated overnight with
0.5 µM each of fluorophores LD550-CoA and LD650-CoA and 5 µM of the labeling enzyme AcpS. To
facilitate surface-immobilization of labeled virions for imaging, DSPE-PEG2000-biotin (Avanti Polar
Lipids, Alabaster, AL, USA) lipid was added to samples and incubated at room temperature for 30
min. Labeled virus was purified from unbound fluorophores and lipid by ultracentrifugation through
a 6–30% OptiPrep (Millipore Sigma, Burlington, MA, USA) density gradient for 1 h at 35,000× g, and
virus-containing fractions were identified by immunoblot for GP and p24.
2.9. smFRET Imaging
Purified and labeled GP∆TM or pseudovirus was immobilized and imaged using wide-field
prism-based TIRF, as described [23]. smFRET data were acquired at room temperature using
Metamorph software (Molecular Devices, San Jose, CA, USA) for 40 s at 25 frames/s. To generate
pseudovirions containing GPCL, virus was treated with thermolysin as described above, terminated
with phosphoramidon, and either imaged immediately or incubated with 1.7 µM (80 µg/mL) purified
NPC1-C for 30 min at room temperature immediately prior to surface immobilization and imaging. For
conditions containing monoclonal antibody, the indicated antibody was diluted in imaging buffer and
incubated with surface immobilized pseudovirions for 30 min at room temperature immediately prior
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to imaging. KZ52 was prepared as described above. Purified c2G4 and c4G7 were provided by Mapp
Biopharmaceutical (San Diego, CA, USA). Purified ADI-15946, ADI-15878, ADI-15742, ADI-15750, and
ADI-16061 were provided by Adimab (Lebanon, NH, USA).
2.10. Analysis of smFRET Data
All smFRET data was processed and analyzed using the SPARTAN software package (https://www.
scottcblanchardlab.com/software) in Matlab (Mathworks, Natick, MA, USA) [24]. smFRET trajectories
were identified according to four criteria: (i) exceeded a minimum total fluorescence intensity; (ii)
duration of smFRET trajectory exceeded 15 frames; (iii) correlation coefficient calculated from the
donor and acceptor fluorescence trajectories was less than −0.1; and (iv) signal-to-noise ratio was
greater than 8. Due to greater heterogeneity in the smFRET data acquired on pseudovirion-associated
GP, trajectories that passed these criteria where then verified manually. Hidden Markov model
(HMM) selection was performed using the Baum-Welch algorithm, with correction of the maximized
log-likelihood for different numbers of model parameters using the Akaike information criterium
(AIC) [25]. smFRET trajectories were idealized to the determined model using the segmental k-means
algorithm [26] implemented in SPARTAN.
2.11. Molecular Dynamics Simulation of Fluorescently Labeled GP∆TM
Atomic coordinates were obtained from a structure of GP∆TM determined by X-ray crystallography
(PDB accession 5JQ3) [11]. Amino acids corresponding to the A1 (GDSLDMLEWSLM) and A4
(DSLDMLEW) peptides were attached to the N termini of GP1 and GP2, respectively in PyMol (version
2.3.1, Schrödinger, Cambridge, MA, USA). Atomic models of LD550- and LD650-maleimide with a
phosphopantetheinyl linker were constructed in PyMol (verson 2.3.1, Schrödinger, Cambridge, MA,
USA). The fluorophore geometries were initially optimized at the AM1 level of theory with the sqm
program in AmberTools (version 16, San Francisco, CA, USA). The geometries were further optimized,
and the electrostatic potential (ESP) calculations were performed at the HF/6-31G (d) level of theory
in Gaussian 9 (Gaussian, Inc., Wallingford, CT, USA). Partial atomic charges were then derived by
restrained electrostatic potential (RESP) fitting using antechamber in AmberTools. Atom types and
bonded parameters from the Generalized Amber Force Field (GAFF2) were assigned using antechamber
and parmchk2 in AmberTools. The fluorophores and linkers were attached at the serine residue at
positions 3 and 2 of the A1 and A4 peptides, respectively in LEaP. The protein component of the system
was parameterized with the Amber force field (ff14SB). The entire system was charge-neutralized and
solvated in explicit water using the TIP3P model with periodic boundary conditions in LEaP. The
system was energy minimized for 0.1 ns, followed by a 50 ns simulation run in the NPT ensemble, with
temperature and pressure maintained at 300 K and 1 atm through the use of Langevin dynamics and
the Nose’-Hoover Langevin piston method, respectively. Simulations were run using NAMD (version
2.12, Urbana-Champaign, IL, USA) on the Tufts Research Cluster.
3. Results
3.1. Site-Specific Fluorescent Labelling of EBOV GP
The application of smFRET imaging requires site-specific attachment of donor and acceptor
fluorophores to GP. We specifically sought to probe movement of GP1 with respect to GP2, as well as
movement of the viral fusion loop that is proximal to the N terminus of GP2. Both motions are predicted
to be critical to the mechanism of GP-mediated membrane fusion [16]. To this end, we modified GP∆TM
from the Mayinga strain of EBOV for the site-specific attachment of donor and acceptor fluorophores
(Figure 1a). This construct contained deletions of the mucin domain and transmembrane domain, and
included a foldon trimerization peptide and C-terminal 6X His tag, similar to that characterized by
x-ray crystallography but with residue T at position 42 to maintain the native glycosylation site [11].
We inserted the 12-residue A1 peptide into the N terminus of GP1, and the 8-residue A4 peptide into
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the N-terminus of GP2 to generate GP∆TM 32-A1/501-A4 (Figure 1b,c). These peptide tags enable
enzymatic attachment of fluorophore conjugates to a specific serine residue within each peptide [27,28].
Molecular dynamics simulation of GP∆TM in the pre-fusion conformation with the peptide tags and
conjugated fluorophores suggested an inter-fluorophore distance of approximately 30 Å, predictive of
high FRET (Figure 1c).
1 
 
 
 
Figure 1. Site-specific fluorescent labelling of EBOV GP for smFRET. (a) Structural organization of
GP∆TM. Adapted from Ref. [11]. FL, fusion loop; SP, signal peptide; TM, transmembrane helix. (b)
EBOV GP∆TM and GP∆muc were modified to contain peptide tags (bold) in GP1, between amino
acid position 32 and 33, and in GP2, between amino acid positions 501 and 502, to facilitate enzymatic
labelling with fluorophores at the serine residues highlighted in red. (c) Surface rendering of EBOV
GP∆TM (derived from PDB accession 5JQ3 [11]) with fluorophores attached. MD simulation of
fluorescently labeled GP∆TM 32-A1/501-A4 predicts an inter-fluorophore distance of approximately 30
Å. After minimization and equilibration, the time-averaged distance between the centers of mass of the
fluorophores was determined through a 50-ns simulation (see Section 2).
We next verified that these peptide-insertion sites did not disrupt GP function by creating analogous
insertions in full-length, transmembrane-intact GP∆muc (i.e., GP∆muc 32-A1/501-A4). When expressed
either GP∆muc 32-A1/501-A4 or untagged GP∆muc on pseudovirions using a recombinant vesicular
stomatitis virus (rVSV) core that encodes GFP [24]. Pseudovirions containing GP∆muc 32-A1/501-A4
maintained infectivity levels comparable to those bearing untagged GP∆muc (Figure 2a). Since the low
density of glycoproteins on the surface of retroviral particles provides the best platform for smFRET
imaging, we formed HIV-1 particles pseudotyped with GP∆muc 32-A1/501-A4 and characterized
incorporation into virus particles, cleavage of the glycan cap by thermolysin, sensitivity to neutralization
by a panel of antibodies, and NPC1-C binding (Figure 2b–d). In all cases, pseudovirion-associated
GP∆muc 32-A1/501-A4 maintained phenotypes comparable to wild-type GP∆muc.
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mean ± standard error (n = 3). (b) Western blot of retroviral pseudovirions containing GPΔmuc, 
GPΔmuc 32-A1/501-A4 or no GP after 1 h mock treatment (−) or treatment with thermolysin (+) to 
cleave the glycan cap and generate GPCL. The HIV structural protein p24 indicates the total amount 
of virus loaded. (c) Neutralization of retroviral pseudoparticles by monoclonal antibodies. Antibodies 
were tested at 15 µg/mL for neutralizing activity against retroviral pseudoparticles containing either 
GPΔmuc (black bars) or GPΔmuc 32-A1/501-A4 (red bars). Luciferase activity was detected 48 h post-
infection and expressed as a percentage of infection with no antibody (No Ab). Results are shown as 
the mean ± standard error (n = 2). (d) ELISA for NPC1-C binding to retroviral pseudovirions 
containing only GPΔmuc or GPΔmuc 32-A1/501-A4, with or without thermolysin treatment to 
generate GPCL or GPCL 32-A1/501-A4. Results are shown as the mean ± standard error (n = 3). 
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FRET state (0.74 ± 0.08) with 52.6% occupancy, as displayed in histograms of the FRET values 
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consistent with the ~30 Å inter-fluorophore distance predicted by molecular dynamics simulation of 
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[2,11,14]. We also observed two additional states, 0.27 ± 0.08 and 0.50 ± 0.08 FRET, suggestive of 
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Figure 2. Characterization of pse ovirions containing peptide tags for site-specific fluorophore
attachment. (a) Infectivity of pseudovirions containi g either GP∆muc or GP∆muc 32-A1/501-A4 using
a recombinant vesicular stomatitis virus (VSV) core that encodes GFP. Viral infectivity was determined
by count g eGFP-positive Vero cells 14–16 h post infection. Results are shown as the mean ± standard
error ( = 3). (b) Western blot of retroviral pseudovirions containing GP∆muc, GP∆muc 32-A1/501-A4
or no GP after h mock treatment (−) or treatment with thermolysin (+) to cleave the glycan cap
and generate GPCL. The HIV structural protein p24 indic tes the total amount of virus loaded. (c)
Neutralization of retrovir l pseud particles by mon clonal antibodies. Antibodies were teste at 15
µg/mL for neutralizing activity against retroviral pseudoparticles containing either GP∆muc (black
bars) or GP∆muc 32-A1/501-A4 (red bars). Luciferase activity was detected 48 h post-infection and
expressed as a percentage of infection with no antibody (No Ab). Results are shown as the mean ±
standard error (n = 2). (d) ELISA for NPC1-C binding to retroviral pseudovirions containing only
GP∆muc or GP∆muc 32-A1/501-A4, with or without thermolysin treatment to generate GPCL or GPCL
32-A1/501-A4. Results are shown as the mean ± standard error (n = 3).
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plasmids encoding GP∆T 32-A1/501-A4 and untagged GP∆TM at a ratio of 1:2 (Section 2). This
was found to optimize the proportion of GP∆TM trimers containing a single GP∆TM 32-A1/501-A4
protomer. smFRET measurements could then be made that originated from a single donor-acceptor
fluorophore pair on the same GP∆TM protomer (Figure 3a), as previously described for studies of other
envelope glycoproteins on the surface of virions [22,23]. Trimers containing enzymatically attached
fluorophores were surface immobilized and imaged by prism-based total internal reflection fluorescence
(TIRF) microscopy (Section 2) (Figure 3a). We confirmed by western blot that the sample of GP∆TM
used in smFRET imaging contained minimal amounts of GP0 and remained intact during protein
expression and purification (Figure 3b). We observed smFRET trajectories indicating intrinsic and
spontaneous fluctuations between multiple FRET states during the observation period of approximately
20 s (Figure 3c). Hidden Markov modeling (HMM) indicated a predominant high-FRET state (0.74
± 0.08) with 52.6% occupancy, as displaye in histograms of the FRET values compiled from the
populatio of observed molecules (Figure 3d, left). This high-FRET state is consistent with the ~30
Å inter-fluorophore istance predicted by m lecula dynamics simulation of fluorescently labeled
GP in the conformation determined by x-r y crystallography (Figure 1c) [2,11,14]. We also observed
two additional states, 0.27 ± 0.08 and 0.50 ± 0.08 FRET, sugg stiv of alternative GP conformations in
which the distance between the fluorophor pair increases. Th intermedi te- and low-FRET states
were present with occupancies of 26.9% and 20.5%, respectively (Table 1). A transition density plot
(TDP) displays the relative frequencies of observed transitions within this population of trimers. The
TDP shows roughly equal transition frequencies between the high- and intermediate-FRET states, and
between the intermediate- and low-FRET states; transitions directly between the high- and low-FRET
states were rarely seen (Figure 3d, right). The TDP is symmetric about the diagonal axis, which
indicates equilibrium dynamics between multiple states. These data suggest that pre-fusion GP∆TM
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is intrinsically dynamic, sampling two conformations in addition to that which has been described
by crystallography.Viruses 2020, 12, x FOR PEER REVIEW 8 of 15 
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Figure 3. Conformational dynamics of EBOV GP∆TM. (a) smFRET imaging of GP∆TM trimers
containing a single fluorescently-labelled protomer within an otherwise wild-type GP∆TM trimer were
surface-immobilized via biotin-NTA on a streptavidin-coated quartz microscope slide for smFRET
imaging with TIRF microscopy. (b) Western blot of purified GP∆TM used in smFRET imaging
using an anti-GP1 antibody (H3C8). (c) Representative fluorescence trace (top) showing fluorescence
intensity over time for a donor (LD550; green) and acceptor (LD650; red) fluorophore pair on a single
GP∆TM trimer, and the corresponding FRET trajectory (bottom). Overlaid on the FRET trajectory
is the idealization (red) resulting from HMM analysis. (d) (Left) P pulation FRET histogram for
GP∆TM trimers composed of FRET trajectories sum ed over the observation window. Overlaid on
the histograms are Gaussian distributions with me ns 0.3, 0.5 and 0.7 that reflect the results of HMM
analysis. N indicates the number of trimers in the popula ion histogram. (Right) Transition density
plot (TDP) displ ying the relative frequ ncies of observed tra sitions generated from idealizations
of ind vidual FRET trajectories. N indica es the total number of transitions wi hi the population of
tri ers nalyzed.
Table 1. Förster resonance energy transfer (FRET) state occupancies determined through hidden
Markov modeling.
Occupancies (%)
Low FRET Intermediate FRET High FRET
GP∆TM 20.5% 26.9% 52.6%
GP∆muc 31.4% 23.6% 45.0%
GPCL 22.2% 45.8% 32.0%
GPCL + NPC1-C 19.8% 53.4% 26.8%
GP∆muc + KZ52 (15 µg/mL) 35.7% 23.3% 41.0%
GP∆muc + KZ52 (500 µg/mL) 42.0% 23.2% 34.8%
GP∆muc + c2G4 46.7% 24.9% 28.4%
GP∆muc + c4G7 47.2% 25.6% 27.2%
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Table 1. Cont.
Occupancies (%)
Low FRET Intermediate FRET High FRET
GP∆muc + ADI-15946 27.1% 25.0% 47.9%
GP∆muc + ADI-15878 20.8% 20.2% 59.0%
GP∆muc + ADI-15742 21.8% 23.3% 49.3%
GP∆muc + ADI-15750 41.4% 23.6% 35.0%
GP∆muc + ADI-16061 32.0% 23.1% 44.9%
3.3. Conformational Dynamics of Pseudovirion-Associated EBOV GP∆muc
We next asked whether the dynamics observed for GP∆TM are representative of full-length
functional GP∆muc. We therefore transferred the same fluorophore attachment strategy to GP∆muc
on the surface of retroviral pseudovirions. As done previously for influenza hemagglutinin and
HIV Env [22,23], we formed pseudovirions with the HIV core and an excess of wild-type GP∆muc
over GP∆muc 32-A1/501-A4 (Section 2). This dilution of GP∆muc 32-A1/501-A4 with wild-type
GP∆muc maximized the probability that only a single fluorophore pair was present on the surface of
each virion (Figure 4a). Similar to the data for GP∆TM, we observed smFRET trajectories indicating
intrinsic and spontaneous fluctuations between multiple FRET states (Figure 4b). Notably, HMM
analysis of the smFRET trajectories revealed the same low- (0.28 ± 0.07), intermediate- (0.50 ± 0.08) and
high- (0.73 ± 0.08) FRET states as observed for GP∆TM (Figure 3c,d). However, we observed lower
intrinsic occupancy of the high-FRET state, higher occupancy in the low-FRET state, and slightly lower
occupancy of the intermediate-FRET state as compared to GP∆TM (Table 1). The TDP indicates that
transitions occur between all three FRET states, with transitions between high and intermediate FRET,
and between intermediate and low FRET being most frequent (Figure 4b). These data suggest that
pre-fusion, unliganded GP∆muc, similarly to GP∆TM, can spontaneously and reversibly transition
between multiple conformations on the surface of pseudovirions.
3.4. Effects of Proteolytic Cleavage and NPC1 Binding on EBOV GP∆muc Conformation
We next examined whether proteolytic removal of the glycan cap and subsequent binding to
soluble NPC1-C (sNPC1-C) induce conformational changes in GP∆muc. We treated the pseudovirions
with thermolysin to generate GPCL immediately prior to smFRET imaging (Section 2). Individual traces,
as well as the population FRET histogram, showed increased occupancy in the intermediate-FRET state
for GPCL as compared to GP∆muc (Figure 4c). Also notable from the TDP was a decrease in the overall
level of dynamics, indicated by reduced probability density for all observed transitions. This reflects a
reduction in the number of transitions between each FRET state compared to GP∆muc (Figure 4b).
Again, the observed transitions occurred primarily between the intermediate- and high-FRET states
and were rarely detected between the low- and high-FRET states. We then asked whether NPC1
binding might further remodel GP conformation. We observed that addition of sNPC1-C to GPCL
further promoted an intermediate-FRET state and reduced the occupancy of the low- and high-FRET
states (Figure 4d). Equally as dramatic was the reduction in the level of overall dynamics, as depicted in
the TDP. These data demonstrated that proteolytic removal of the glycan cap destabilizes the high-FRET
conformation preferred by uncleaved GP∆muc. NPC1 binding further destabilizes this state.
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Structural models and smFRET data for GPCL bound to sNPC1-C. Structural models were adapted
from PDB accessions 5JQ3 and 5F1B [11,14]. Approximate location of the viral membrane is shown.
3.5. Neutralizing Antibodies Mediate GP Conformation
We next asked whether nAbs might function by remodeling GP in a manner that is distinct from
proteolytic cleavage and NPC1 binding. In particular, antibodies that interact with GP proximal
to the fusion loop are predicted to function by preventing conformational changes necessary for
membrane fusion. The antibody KZ52 showed a modest concentration-dependent stabilization of the
low-FRET state, which was most pronounced at the saturating concentration of 500 µg/mL (Figure 5a).
This mild effect on GP conformation is consistent with reports of KZ52 incompletely neutralizing
EBOV [19,29]; KZ52 may also function by limiting proteolytic cleavage by cathepsins [30]. Additional
nAbs were tested at 15 µg/mL, a concentration that yields minimally 90% neutralization (Figure 2b).
The base-binding antibodies c2G4 and c4G7 [31,32] also stabilized the low-FRET state, to a greater
extent than KZ52 (Figure 5a). In contrast, ADI-15946, an antibody that competes with KZ52 but bridges
the GP1 core and glycan cap [33–35], modestly stabilized the high-FRET state. We also tested nAbs
ADI-15878 and ADI-15742, which contact the GP2 fusion loop and adjacent GP1 protomer [33,34,36].
These nAbs significantly increased the occupancy in the high-FRET state (Figure 5b). The glycan-cap
binding nAb ADI-15750 slightly stabilized the low-FRET state (Figure 5c) [33]. Finally, the GP2
stalk-binding nAb ADI-16061 (Figure 5d) showed no detectable change in FRET-state occupancy
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compared to unliganded GP, indicating that the current fluorophore placement does not report on
its mechanism of action [33]. In all cases, transitions to all three FRET states persisted as indicated
by the TDPs. Notably, all the nAbs tested stabilized states distinct from proteolytic cleavage and
NPC1-C binding. This suggests that their mechanisms of action may be to inhibit transition to the
intermediate-FRET conformation.Viruses 2020, 12, x FOR PEER REVIEW 11 of 15 
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Figure 5. Neutralizing antibodies stabilize distinct EBOV GP∆muc conformations. Population FRET
histograms and corresponding TDPs, displayed as in Figures 3 and 4, for EBOV GP∆muc in the
presence of 15 µg/mL (unless otherwise noted) of the following: (a) Base-binding antibodies KZ52,
c2G4, c4G7, and ADI-15946; (b) base-binding antibodies that contact the GP2 fusion loop and adjacent
GP1 protomer ADI-15878 and ADI-15742; (c) Glycan-cap-binding antibody ADI-15750; and (d) GP2
stalk-binding antibody ADI-16061.
4. Discussion
The spring-loaded mechanism of type-I viral fusogens, based largely on studies of influenza
hemagglutinin, predicts that dissociation of GP1 from GP2 permits refolding of GP2, which moves
the fusion loop toward the target membrane [37]. Structures of pre- and post-fusion GP support
this model [2,11,14,18]. The site-specific placement of fluorophores at the N termini of GP1 and GP2
allowed us to visualize movement of the N terminus of GP2, which is proximal to the fusion loop,
and the movement of GP1 with respect to GP2. We therefore anticipate that the dynamics observed
here reflect conformational changes in GP that relate to its mechanism of membrane fusion. Our
approach compliments previous studies of GP by accounting for several key features: (i) real-time
changes in GP conformation on the timescale of 10–100 milliseconds; (ii) the use of GP∆TM as well as
GP∆muc with an intact transmembrane and cytoplasmic region, which permits their direct comparison;
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(iii) the functionally relevant context of a viral membrane; and (iv) measurements on single trimers,
which precludes the need for averaging measurements from a population of asynchronous trimers.
Our results indicate that GP samples multiple conformations beyond what has been described in
structural investigations. Molecular modeling supports the identification of the high-FRET state
as the conformation depicted in the crystal structures of GP, with the fusion loop positioned in a
hydrophobic cleft and contacting the neighboring GP promoter. While the high-FRET state has the
highest occupancy for both GP∆TM and GP∆muc, our comparison indicates that the presence of the
transmembrane domain shifts the conformational equilibrium away from the conformation described
by crystallography and favors transition to an alternative conformation.
In order to fully capture the conformational dynamics of complex macromolecules, multiple
smFRET signals, stemming from distinct fluorophore attachment strategies are necessary. A parallel
study used smFRET imaging with both fluorophores attached to GP2 and was thus insensitive to
inter-domain movements [38]. This study indicated no conformational change upon cleavage of the
glycan cap. This suggests that the conformational shift toward intermediate FRET seen upon glycan
cap cleavage in the present study mainly reflects repositioning of GP1 with respect to GP2. This
rearrangement may aid in priming GP1 for interaction with NPC1, and in facilitating other downstream
events related to fusion. Recent structural modeling suggests that movement of the fusion loop away
from the surface of the virion would require outward motion of GP1, but not necessarily GP1 release,
in order to allow the fusion loop access to the space above the GP core [39]. Our results confirm that
GP1 does not dissociate from GP2 at this stage, since we still observe reversible transitions into and out
of intermediate FRET. Removal of the glycan cap may therefore relieve a physical restriction on the
movement of GP2 [40], allowing the fusion loop greater mobility. Das et al. also reported a dramatic
repositioning of the GP2 N terminus upon sNPC1-C binding [38]. Thus, the effect of glycan cap cleavage
seen in the present study may potentiate GP2 rearrangements promoted by NPC1 binding. The further
stabilization of intermediate FRET seen here upon sNPC1-C binding would then reflect additional
conformational rearrangements in GP1 and GP2, which result in no detectable change in FRET with
the current fluorophore attachment strategy and signal-to-noise ratio. However, when the results of
the present study and those of Das et al. are interpreted together, a more complete understanding
emerges of the independent effects of glycan cap cleavage and NPC1 binding, respectively. In summary,
the current data support the idea that the glycan cap plays an essential role beyond obscuring the
receptor-binding site. Specifically, the glycan cap mediates the pre-fusion conformational dynamics
of GP, limiting transition to conformations that are putatively on pathway to fusion. An intriguing
possibility is that the glycan cap serves to prevent spontaneous triggering of GP prior to arrival of
EBOV in the late endosome, at which point the glycan cap is removed by the cellular cathepsins.
In contrast to glycan cap removal and sNPC1-C binding, the nAbs tested here that alter GP
conformation either enrich the low-FRET (KZ52, c2G4, and c4G7) or high-FRET (ADI-15878 and
ADI-15742) states. We cannot exclude the possibility that base-binding nAbs may cause local changes in
the regions of fluorophore attachment. Therefore, it remains possible that the high- and low-FRET states
result from local changes in conformation or fluorophore orientation rather than global changes in GP
conformation. In either case, these data support the idea that the mechanism of neutralization by these
nAbs is to inhibit transition to conformations, such as the intermediate-FRET state, that are relevant to
the fusion reaction [10]. At present we cannot rule out the possibility that the neutralizing antibodies
enrich for conformations that are distinct from those seen for unliganded and receptor-bound GP,
but which are not distinguishable using the current fluorophore placement. The use of additional
fluorophore attachment sites in GP1 and GP2, as well as unbiased molecular modeling and structural
techniques will further resolve conformations of GP in bound and unliganded states without relying
on pre-existing conformations of GP that are favored under conditions of crystal formation. smFRET
imaging provides a unique platform for evaluating GP ligands and mutant GP variants that stably
present antigenic conformations and should thus find utility in future studies designing novel vaccine
candidates and antiviral therapeutics that target GP. Taken together, these observations demonstrate that
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the activity of GP in membrane fusion is regulated by ligands that modulate the intrinsic conformational
dynamics of GP. smFRET imaging provides a unique platform for evaluating GP ligands and mutant
GP variants that stably present antigenic conformations and should thus find utility in future studies
designing novel vaccine candidates and antiviral therapeutics that target GP.
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